Abstract:The periostin protein, encoded by the POSTN gene, is a component of the extracellular matrix, which is expressed by fibroblasts and has been observed in a variety of human malignancies. The present study aimed to detect the expression of periostin in the tissues of non-small cell lung cancer (NSCLC) patients and benign lung tumors, and to correlate the results with the clinicopathological data of the subjects, in order to evaluate periostin as a potential prognostic marker. In total, 49 NSCLC patients and 6 benign lung tumors were included in this study. The protein level of periostin was detected in paired normal/paratumor/cancer tissues by a western blot analysis and the mRNA level in paired normal/cancer tissues was detected by quantitative polymerase chain reaction (qPCR). The results were then correlated with established biological and prognostic factors. Immunohistochemistry was used to confirm the location of periostin in the NSCLC tissues. Uni- and multivariate analyses were performed using Cox's proportional hazards regression model. The protein level of periostin was elevated in the cancer tissue of the NSCLC patients compared with the normal (P=0.017) and paratumor (P=0.000) tissues. The expression level in the male patients was much higher than in the female patients at the protein (P=0.001) and mRNA (P=0.010) levels. The mRNA level in the non-adenocarcinoma (non-ADC) patients was much higher than in the adenocarcinoma (ADC) patients (P=0.029). Periostin was demonstrated higher expression at the protein level in the pseudotumors and tuberculosis patients than in the adjacent (P=0.016) and surrounding tissues (P=0.001). Immunostaining indicated that high levels of periostin were present in the mesenchymal areas, but not in the cancer cells themselves. The patients with tumors exhibiting high-level periostin expression showed a significantly shorter survival time (P=0.036, log-rank test). The 3-year survival rate was 81.5% for patients with low-level periostin expression (periostin-L; n=27) and 45.4% for patients with high-level periostin expression (periostin-H; n=22). Similarly, pathological node (pN) status was a significant prognostic marker in the univariate Cox survival analysis. Notably, periostin-H expression was also identified as an independent prognostic factor by the multivariate analysis (P=0.011). These results showed that the overexpression of periostin predicts a poor prognosis, therefore it may be regarded as a novel molecule in the progression and development of NSCLC. The results provide an additional target for the adjuvant treatment of NSCLC.

Decreased expression of speckle-type POZ protein for the prediction of poor prognosis in patients with non-small cell lung cancer

DECREASED EXPRESSION OF THE SPECKLE-TYPE POZ PROTEIN IS ASSOCIATED WITH POOR PROGNOSIS IN BLADDER CANCER

Speckle-type POZ Protein is Negatively Associated with Malignancies and Inhibits Cell Proliferation and Migration in Liver Cancer

Speckle-type POZ protein functions as a tumor suppressor in non-small cell lung cancer due to DNA methylation

Expression of speckle-type POZ protein in bladder cancer

SPOP Suppresses Pancreatic Cancer Progression by Promoting the Degradation of NANOG.

SPOP Suppresses Tumorigenesis by Regulating Hedgehog/Gli2 Signaling Pathway in Gastric Cancer.

Speckle-type POZ protein suppresses hepatocellular carcinoma cell migration and invasion via ubiquitin-dependent proteolysis of SUMO1/sentrin specific peptidase 7

SMOX expression predicts the prognosis of non-small cell lung cancer

Effect of speckle-type POZ protein on cell proliferation and migration in bladder cancer cell T24

Differential expression of speckled POZ protein, SPOP: Putative regulation by miR-145

SPOP Promotes Cervical Cancer Progression by Inducing the Movement of PD-1 Away from PD-L1 in Spatial Localization

Speckle-type POZ adaptor protein (SPOP) and its role in cancer

Loss of Speckle-Type POZ Protein Promotes Prostate Cancer Cell Migration and Invasion Through Upregulation of MCP-1

The diverse roles of SPOP in prostate cancer and kidney cancer

Abstract P2-16-03: The Speckle-type POZ protein (SPOP) inhibits breast cancer malignancy by destabilizing oncogene TWIST1

The emerging role of SPOP protein in tumorigenesis and cancer therapy

TGF-β signaling regulates SPOP expression and promotes prostate cancer cell stemness

S119N Mutation of the E3 Ubiquitin Ligase SPOP Suppresses SLC7A1 Degradation to Regulate Hepatoblastoma Progression

SPOP Promotes Tumorigenesis by Acting As a Key Regulatory Hub in Kidney Cancer

Overexpression of Periostin Predicts Poor Prognosis in Non-Small Cell Lung Cancer.